Valeritas (NASDAQ:VLRX) posted its earnings results on Tuesday. The company reported ($1.91) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.52) by $0.61, Yahoo Finance reports. Valeritas had a negative return on equity of 45,700.07% and a negative net margin of 187.83%. The business had revenue of $8.46 million during the quarter.
Valeritas stock traded down $0.02 during midday trading on Wednesday, hitting $1.48. 3,567 shares of the company’s stock were exchanged, compared to its average volume of 304,997. Valeritas has a 52-week low of $1.10 and a 52-week high of $19.60. The stock has a 50-day moving average price of $1.39 and a two-hundred day moving average price of $2.02. The company has a debt-to-equity ratio of 29.19, a quick ratio of 2.06 and a current ratio of 2.58. The company has a market cap of $10.74 million, a P/E ratio of -0.04 and a beta of 1.93.
Several equities analysts recently commented on the company. BTIG Research restated a “buy” rating and set a $14.00 target price on shares of Valeritas in a research report on Sunday, August 11th. ValuEngine upgraded Valeritas from a “hold” rating to a “buy” rating in a research report on Wednesday, September 4th. Finally, Zacks Investment Research upgraded Valeritas from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Sunday, November 3rd.
Valeritas Company Profile
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization.
See Also: What is the Book Value of a Share?
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.